StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Gyre Therapeutics's EV/EBITDA was 231.5× on Jul 31, 2026, against 51.9× a year earlier. Over the last 4 years it ranged from 1.7× to 271.5×, with a median of 48.0×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 2026231.5×+108.7
2025Dec 31, 2025122.8×−7.6
2024Jan 31, 2024130.4×−141.1
2023Dec 29, 2023271.5×+252.1
2022Dec 30, 202219.4×−54.5
2013Jan 31, 201374.0×+10.2
2012Dec 31, 201263.8×+62.1
2011Dec 30, 20111.7×–

More Gyre Therapeutics figures

See a number that looks wrong?